UPPSALA, Sweden, Aug. 29, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the amorphOX® drug delivery platform.
Read more at prnewswire.comOrexo secures patent protection in the US for OX640, a nasal epinephrine powder product
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here